Sands Capital Management
SRPT icon

Sands Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Sands Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-874,765
Closed -$121M – 68
2023
Q1 		$121M Sell
874,765
-1,276,613
-59% -$166M 0.4% 49
2022
Q4 		$279M Sell
2,151,378
-330,997
-13% -$38.4M 1.05% 30
2022
Q3 		$274M Sell
2,482,375
-1,228,726
-33% -$124M 1.03% 33
2022
Q2 		$278M Sell
3,711,101
-1,071,850
-22% -$78.9M 0.96% 32
2022
Q1 		$374M Sell
4,782,951
-581,676
-11% -$44.5M 0.86% 35
2021
Q4 		$483M Sell
5,364,627
-201,476
-4% -$17.2M 0.9% 35
2021
Q3 		$515M Sell
5,566,103
-41,045
-0.7% -$3.16M 0.86% 35
2021
Q2 		$436M Buy
5,607,148
+2,579,058
+85% +$196M 0.74% 38
2021
Q1 		$226M Buy
3,028,090
+2,050,954
+210% +$189M 0.44% 49
2020
Q4 		$167M Sell
977,136
-888,327
-48% -$132M 0.32% 50
2020
Q3 		$262M Sell
1,865,463
-2,473,793
-57% -$376M 0.57% 45
2020
Q2 		$696M Sell
4,339,256
-63,675
-1% -$8.66M 1.68% 23
2020
Q1 		$431M Sell
4,402,931
-154,568
-3% -$17.7M 1.44% 25
2019
Q4 		$588M Buy
4,557,499
+605,409
+15% +$61.1M 1.71% 23
2019
Q3 		$298M Buy
3,952,090
+426,514
+12% +$50.4M 0.96% 32
2019
Q2 		$536M Sell
3,525,576
-91,518
-3% -$11.1M 1.59% 22
2019
Q1 		$431M Buy
3,617,094
+522,327
+17% +$67.2M 1.33% 24
2018
Q4 		$338M Buy
3,094,767
+1,193,203
+63% +$149M 1.21% 26
2018
Q3 		$307M Buy
+1,901,564
New +$260M 0.87% 33

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management's SRPT Position: Q2 2023 in Review

Sands Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 874,765 shares — an estimated $121M sold.

Sands Capital Management first reported a position in SRPT in Q3 2018 and held it in 19 quarters. The position peaked at $696M in Q2 2020. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • Sands Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Sands Capital Management sold 874,765 Sarepta Therapeutics shares in Q2 2023, an estimated $121M.
  • Sands Capital Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 19 quarters.
  • Sands Capital Management's Sarepta Therapeutics position peaked at $696M in Q2 2020.
  • 404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Sands Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.